4,4'-Dimethylaminorex

4,4'-Dimethylaminorex
Clinical data
Other names	4,4'-DMAR
ATC code	none;
Legal status
Legal status	BR: Class F2 (Prohibited psychotropics); DE: Anlage II (Authorized trade only, not prescriptible); UK: Class A; US: Schedule I; Illegal in Czech Republic and Sweden;
Identifiers
	IUPAC name 4-Methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine;
CAS Number	1445569-01-6 ;
PubChem CID	20741615;
ChemSpider	19546433;
UNII	18Y239214S;
KEGG	C22805;
CompTox Dashboard (EPA)	DTXSID901031562 ;
Chemical and physical data
Formula	C11H14N2O
Molar mass	190.246 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(N=C(N)O1)C1C2=CC=C(C)C=C2;
	InChI InChI=1S/C11H14N2O/c1-7-3-5-9(6-4-7)10-8(2)13-11(12)14-10/h3-6,8,10H,1-2H3,(H2,12,13); Key:NPILLHMQNMXXTL-UHFFFAOYSA-N;

4,4'-Dimethylaminorex (abbreviated as 4,4'-DMAR), sometimes referred to by the street name "Serotoni", is a psychostimulant and entactogen designer drug related to aminorex, 4-methylaminorex, and pemoline. It was first detected in the Netherlands in December 2012, and has been sold as a designer drug around Europe since mid-2013.

4,4'-DMAR had been linked to at least 31 deaths in Hungary, Poland, and the UK by February 2014, mostly when consumed in combination with other drugs. Nineteen deaths linked to 4,4'-DMAR were reported in Northern Ireland in the same time period.